RGT 0.00% 29.0¢ argent biopharma limited

Ann: Appendix 4E and Audited 2016 Financial Report-MXC.AX, page-2

  1. 219 Posts.
    lightbulb Created with Sketch. 1
    Some interesting facts coming out of this or at least nicely documented and not sure if has been mentioned previously.

    The white paper with the USyd business school looks like a good off-sided benefit for all cannabis companies in Australia, giving a value to potential medical cannabis market in Australia and provides a good talking point for the industry as a whole.

    The assets liabilities ratio is looking good with $8million in cash with loss previous year of $6million so we have a decent amount of money to stretch us through the next financial year. That coupled with expected revenue from the derma product lines
    "The Californian distribution deal’s first-year contract is worth approximately €1.2m and the Company expects further revenue uplift in the year ahead."
 
watchlist Created with Sketch. Add RGT (ASX) to my watchlist
(20min delay)
Last
29.0¢
Change
0.000(0.00%)
Mkt cap ! $13.31M
Open High Low Value Volume
29.0¢ 29.0¢ 29.0¢ $22 75

Buyers (Bids)

No. Vol. Price($)
5 6566 29.0¢
 

Sellers (Offers)

Price($) Vol. No.
30.5¢ 44617 1
View Market Depth
Last trade - 12.25pm 05/07/2024 (20 minute delay) ?
RGT (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.